MEPs water down price transparency proposal as clash with ministers looms
This article was originally published in Scrip
Executive Summary
An influential European Parliament committee has rejected proposals by the European Commission to reduce maximum pricing and reimbursement times for new medicines, and has also watered down plans to enforce those times more strictly. The committee did, however, come out in favour of shorter decision-making periods for generic drugs, and called for greater transparency on conflicts of interest within decision-making bodies.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.